Novonesis (NSIS) AGM 2022 summary
Event summary combining transcript, slides, and related documents.
AGM 2022 summary
26 Oct, 2026Financial performance review
Audited annual report for FY2021 approved by shareholders.
Profit distribution approved, including a dividend of DKK 5.50 per DKK 2 share, up 5% vs 2020.
Board and executive committee updates
Jørgen Buhl Rasmussen and Cornelis (Cees) de Jong re-elected as Chair and Vice Chair, respectively.
Heine Dalsgaard, Sharon James, Kasim Kutay and Kim Stratton re-elected as Board members; Morten Sommer elected.
Following the AGM, the Board comprised Jørgen Buhl Rasmussen, Cornelis (Cees) de Jong, Heine Dalsgaard, Sharon James, Kasim Kutay, Morten Sommer and Kim Stratton.
Dividend announcements
Ordinary dividend of DKK 5.50 per DKK 2 share approved, a 5% increase compared with 2020.
Distribution of extraordinary dividends approved.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Novonesis
- 9M organic growth reached 7% and margin 37.9%; Human Health weakness and investment weighed.NSIS
Q3 2026 - FY2020 report approved; DKK 5.25 dividend retained and Board leadership re-elected.NSIS
AGM 2021 - A DKK 6.00 dividend and key Board and governance resolutions were approved.NSIS
AGM 2023 - Shareholders approved a secondary name and elected four Board leaders.NSIS
EGM 2024 - Raised full-year sales growth outlook to 7-8% after 8% organic growth and EUR 1bn buyback.NSIS
Q2 2026 - Strong 2024 results; shareholders approved the dividend, elections, and key authorizations.NSIS
AGM 2025 - Diversification and innovation support biofuel growth and emerging SAF opportunities.NSIS
Status Update - 2024 outlook upgraded with higher growth and margins, driven by innovation and synergies.NSIS
CMD 2024 - 11% organic sales growth, margin expansion, and a major acquisition highlight Q1 2025.NSIS
Q1 2025